| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8445622 | European Journal of Cancer | 2012 | 10 Pages |
Abstract
These findings are in-line with safety data for bevacizumab plus paclitaxel or capecitabine, reported in previous phase III trials.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
I. Lang, M.J. Inbar, Z. Kahán, R. Greil, S. Beslija, S.M. Stemmer, B. Kaufman, Z. Zvirbule, G.G. Steger, D. Messinger, T. Brodowicz, C. Zielinski,